A prospective, single-arm, multi-center, phase II clinical study for bortezomib combined with CHEP regimen in the treatment of primary peripheral T cell lymphoma

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024800

Enrollment

Unknown

Registered

2019-07-28

Start date

2019-07-25

Completion date

Unknown

Last updated

2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peripheral T cell lymphoma

Interventions

single arm:Bortezomib combined with CHEP regimen

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Aged 18-75 years; Peripheral T cell lymphoma confirmed by histopathology; No previous chemotherapy, radiotherapy, immunotherapy or other anti-tumor therapy; Adequate organ and bone marrow function.

Exclusion criteria

Exclusion criteria: NK/T lymphoma or aggressive natural killer cell leukemia; Accompanied by hemophagocytic syndrome; Primary central nervous system lymphoma or secondary central nervous system involvement; Severe infection or other serious illness.

Design outcomes

Primary

Measure	Time frame
response rate;toxicity;	—

Countries

China

Contacts

Public ContactYang Haiyan

Zhejiang Cancer Hospital

yanghy@zjcc.org.cn+86 13857182590

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026